Mirapex Related Published Studies
Well-designed clinical trials related to Mirapex (Pramipexole)
Comparison of pregabalin with pramipexole for restless legs syndrome. [2014]
Pregabalin versus pramipexole: effects on sleep disturbance in restless legs
syndrome. [2014]
Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis
(EMPOWER): a randomised, double-blind, phase 3 trial. [2013]
Pramipexole in patients with early Parkinson's disease (PROUD): a randomised
delayed-start trial. [2013]
Role and clinical utility of pramipexole extended release in the treatment of
early Parkinson's disease. [2012]
A multicenter randomized placebo-controlled clinical trial of pramipexole for
Tourette's syndrome. [2012]
Efficacy and safety of pramipexole in chinese patients with restless legs
syndrome: results from a multi-center, randomized, double-blind,
placebo-controlled trial. [2012]
Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial. [2011.08.23]
Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial. [2011.08.23]
Pramipexole modulates the neural network of reward anticipation. [2011.05]
Tinnitus control by dopamine agonist pramipexole in presbycusis patients: a randomized, placebo-controlled, double-blind study. [2011.04]
Pramipexole versus ropinirole: polysomnographic acute effects in restless legs syndrome. [2011.04]
Efficacy and augmentation during 6 months of double-blind pramipexole for restless legs syndrome. [2011.04]
Randomized trial of pramipexole for patients with restless legs syndrome (RLS) and RLS-related impairment of mood. [2011.01]
Twice-daily, low-dose pramipexole in early Parkinson's disease: a randomized, placebo-controlled trial. [2011.01]
Efficacy, safety and dose-response of pramipexole in Japanese patients with primary restless legs syndrome: randomized trial. [2011]
The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic
lateral sclerosis. [2011]
Pramipexole versus dual release levodopa in restless legs syndrome: a double
blind, randomised, cross-over trial. [2011]
Extended-release pramipexole in early Parkinson disease: a 33-week randomized
controlled trial. [2011]
Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease. [2010.11.15]
Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson's disease. [2010.10.30]
Rationale for delayed-start study of pramipexole in Parkinson's disease: the PROUD study. [2010.08.15]
Long-term open-label study of pramipexole in patients with primary restless legs syndrome. [2010.07.15]
Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. [2010.06]
Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. [2010.06]
Population in vitro-in vivo correlation model for pramipexole slow-release oral formulations. [2010.02]
Efficacy and safety of pramipexole in Japanese patients with primary restless legs syndrome: A polysomnographic randomized, double-blind, placebo-controlled study. [2010.01]
Rationale for delayed-start study of pramipexole in Parkinson's disease: the
PROUD study. [2010]
Pramipexole for the treatment of depressive symptoms in patients with Parkinson's
disease: a randomised, double-blind, placebo-controlled trial. [2010]
Long-term open-label study of pramipexole in patients with primary restless legs
syndrome. [2010]
Efficacy and safety of pramipexole in Japanese patients with primary restless
legs syndrome: A polysomnographic randomized, double-blind, placebo-controlled
study. [2010]
A dose-ranging study of pramipexole for the symptomatic treatment of restless legs syndrome: polysomnographic evaluation of periodic leg movements and sleep disturbance. [2009.06]
Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. [2009.05]
Dopamine and cognitive functioning in de novo subjects with Parkinson's disease: effects of pramipexole and pergolide on working memory. [2009.04]
Antiparkinsonian drug-induced sleepiness: a double-blind placebo-controlled study of L-dopa, bromocriptine and pramipexole in healthy subjects. [2009.03]
The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies. [2009.01]
Effect of pramipexole on RLS symptoms and sleep: a randomized, double-blind, placebo-controlled trial. [2008.12]
Effect of pramipexole on RLS symptoms and sleep: A randomized, double-blind, placebo-controlled trial. [2008.10.24]
First night efficacy of pramipexole in restless legs syndrome and periodic leg movements. [2007.08]
Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. [2007.06]
Pramipexole in levodopa-treated Parkinson disease patients of African, Asian, and Hispanic heritage. [2007.03]
Efficacy of pramipexole in restless legs syndrome: a six-week, multicenter, randomized, double-blind study (effect-RLS study). [2007.01.15]
Comparison of pramipexole and modafinil on arousal, autonomic, and endocrine functions in healthy volunteers. [2006.11]
Efficacy and safety of pramipexole in restless legs syndrome. [2006.09.26]
Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome. [2006.09]
Efficacy and safety of pramipexole in idiopathic restless legs syndrome: a polysomnographic dose-finding study--the PRELUDE study. [2006.08]
Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study. [2006.05]
A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. [2005.08]
A pilot double-blind placebo-controlled trial of low-dose pramipexole in sleep-related eating disorder. [2005.06]
Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial. [2005.05]
Efficacy screening trials of paroxetine, pentoxifylline, riluzole, pramipexole and venlafaxine in cocaine dependence. [2005.03]
A randomly assigned double-blind cross-over study examining the relative anti-parkinsonian tremor effects of pramipexole and pergolide. [2005.01]
Pramipexole v. levodopa as initial treatment for Parkinson's disease: a randomized clinical-economic trial. [2004.09]
Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. [2004.07.01]
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. [2004.07]
Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. [2004.03]
Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson's disease. [2003.12.15]
Randomized, double-blind, 3-month parallel study of the effects of pramipexole, pergolide, and placebo on Parkinsonian tremor. [2003.11]
Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease. [2003.10]
Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. [2003.07]
Pramipexole in comparison to l-dopa: a neuropsychological study. [2003.04]
Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease. [2003.02]
Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison. [2003]
Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. [2002.06]
Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. [2002.05.14]
Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. [2002.04.03]
Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD. [2001.06.12]
Pramipexole-induced somnolence and episodes of daytime sleep. [2000.07]
Pramipexole in the treatment of restless legs syndrome: a follow-up study. [2000.05]
Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. [2000]
Pramipexole, a nonergot dopamine agonist, is effective against rest tremor in intermediate to advanced Parkinson's disease. [1999.09]
Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study. [1999.04]
Restless legs syndrome improved by pramipexole: a double-blind randomized trial. [1999.03.23]
Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group. [1997.10]
Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group. [1997.09]
Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. [1997.07]
Pramipexole in patients with early Parkinson's disease. [1995.08]
Neuroendocrine and side effect profile of pramipexole, a new dopamine receptor agonist, in humans. [1992.05]
Well-designed clinical trials possibly related to Mirapex (Pramipexole)
Drug safety evaluation of rotigotine. [2012]
Preferential D2 or preferential D3 dopamine agonists in restless legs syndrome. [2011.07.12]
Peripheral biomarkers of cognitive response to dopamine receptor agonist treatment. [2011.04]
Treatment of depressive symptoms in Parkinson's disease. [2011.03]
Evaluation of painful sensory symptoms in restless legs syndrome: experience from two clinical trials. [2011.02]
Effects of acute dopamine-agonist treatment in restless legs syndrome on heart rate variability during sleep. [2011.01]
Treatment of depressive symptoms in Parkinson's disease. [2011]
Evaluation of painful sensory symptoms in restless legs syndrome: experience from
two clinical trials. [2011]
Dopaminergic treatment in idiopathic restless legs syndrome: effects on subjective sleepiness. [2010.11]
Dopaminergic challenges in social anxiety disorder: evidence for dopamine D3 desensitisation following successful treatment with serotonergic antidepressants. [2010.05]
Effects of a dopamine agonist on the pharmacodynamics of levodopa in Parkinson disease. [2010.01]
Dopaminergic treatment in idiopathic restless legs syndrome: effects on
subjective sleepiness. [2010]
Tolerability and safety of ropinirole versus other dopamine agonists and levodopa
in the treatment of Parkinson's disease: meta-analysis of randomized controlled
trials. [2010]
Effects of a dopamine agonist on the pharmacodynamics of levodopa in Parkinson
disease. [2010]
Dopaminergic challenges in social anxiety disorder: evidence for dopamine D3
desensitisation following successful treatment with serotonergic antidepressants. [2010]
Single dose of a dopamine agonist impairs reinforcement learning in humans: evidence from event-related potentials and computational modeling of striatal-cortical function. [2009.07]
Defining the boundaries of the response of sleep leg movements to a single dose of dopamine agonist. [2008.09.01]
Rotigotine transdermal system for the treatment of Parkinson's disease. [2008.05]
Single dose of a dopamine agonist impairs reinforcement learning in humans: behavioral evidence from a laboratory-based measure of reward responsiveness. [2008.02]
Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease. [2008]
Risk factors for somnolence, edema, and hallucinations in early Parkinson disease. [2007.07.10]
The implications of using US-specific EQ-5D preference weights for cost-effectiveness evaluation. [2007.05]
Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. [2006.12]
|